Search
ATX-F8-117
go.drugbank.com/drugs/DB17712ExperimentalATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]
BHV-5000
go.drugbank.com/drugs/DB17817ExperimentalBHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]
CC-115
go.drugbank.com/drugs/DB12740InvestigationalCC-115 has been used in trials studying the treatment of Prostate Cancer, Neoplasm Metastasis, Ewing's Osteosarcoma, Glioblastoma Multiforme, and Chronic Lymphocytic Leukemia, among others.
Nifurizone
go.drugbank.com/drugs/DB19694ExperimentalThe usage of the INN stem '-zone' in the name indicates that Nifurizone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurizone is a 5-nitrofuran derivative. Nifurizone has a monoisotopic molecular weight of 307.09 Da.
Onametostat
go.drugbank.com/drugs/DB21480InvestigationalThe usage of the INN stem '-metostat' in the name indicates that Onametostat is a histone N-methyltransferase inhibitor. … Onametostat is under investigation in clinical trial NCT06788509 (A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring).
Nifurethazone
go.drugbank.com/drugs/DB20112ExperimentalThe usage of the INN stem '-azone' in the name indicates that Nifurethazone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurethazone is a 5-nitrofuran derivative. Nifurethazone has a monoisotopic molecular weight of 269.11 Da.
Neflamapimod
go.drugbank.com/drugs/DB07138InvestigationalNeflamapimod has been used in trials studying the treatment of Alzheimer's Disease and Mild Cognitive Impairment.
AMT-080
go.drugbank.com/drugs/DB17846ExperimentalAMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
CTX130
go.drugbank.com/drugs/DB18627InvestigationalCTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Dezamizumab
go.drugbank.com/drugs/DB15153InvestigationalDezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).